Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance

Metabolism: Clinical and Experimental

Volumn 56, Issue 1, 2007, Pages 77-86

  Surdacki, Andrzej ^a   Stochmal, Ewa ^a   Szurkowska, Magdalena ^a   Bode Böger, Stefanie M ^b   Martens Lobenhoffer, Jens ^b   Stochmal, Anna ^a   Klecha, Artur ^a   Kawecka Jaszcz, Kalina ^a   Dubiel, Jacek S ^a   Huszno, Bohdan ^a   Szybiński, Zbigniew ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HOMOCYSTEINE; INSULIN; N(G),N(G) DIMETHYLARGININE;

ADULT; ANALYTIC METHOD; ANGIOGRAPHY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; CREATININE CLEARANCE; EXPERIMENTATION; FEMALE; GOLD STANDARD; HEART LEFT VENTRICLE CONTRACTION; HEMOCONCENTRATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

ADULT; AGED; ARGININE; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DISCRIMINANT ANALYSIS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HOMOCYSTEINE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 33845203620     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.08.023     Document Type: Article

References (96)

1. Yip J., Facchini F.S., and Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83 (1998) 2773-2776
2. Fontbonne A., Charles M.A., Thibult N., Richard J.L., Claude J.R., Warnet J.M., et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34 (1991) 356-361
3. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
4. Pyorala M., Miettinen H., Laakso M., and Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policemen Study. Circulation 98 (1998) 398-404
5. Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23 (2000) 171-175
6. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329 (1993) 1988-1992
7. Weyer C., Tataranni P.A., Bogardus C., and Pratley R.E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24 (2001) 89-94
8. Fujiwara R., Kutsumi Y., Hayashi T., Nishio H., Koshino Y., Shimada Y., et al. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol 75 (1995) 122-126
9. Seibaek M., Sloth C., Vallebo L., Hansen T., Urhammer S.A., Burchardt H., et al. Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. Am Heart J 133 (1997) 622-629
10. Kowalska I., Prokop J., Bachorzewska-Gajewska H., Telejko B., Kinalska I., Kochman W., et al. Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as predictor for coronary atherosclerosis. Diabetes Care 24 (2001) 897-901
11. Unwin N., Shaw J., Zimmet P., and Alberti K.G.M.M. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19 (2002) 708-723
12. Hanefeld M., Temelkova-Kurktschiev T., Schaper F., Henkel E., Siegert G., and Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16 (1999) 212-218
13. Sasso F.C., Carbonara O., Nasti R., Campana B., Marfella R., Torella M., et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. JAMA 291 (2004) 1857-1863
14. Kanauchi M., Tsujimoto N., and Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 24 (2001) 1620-1623
15. DECODE Study Group. European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 (2003) 688-696
16. Drexel H., Aczel S., Marte T., Benzer W., Langer P., Moll W., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 28 (2005) 101-117
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 26 (2003) 3160-3167
18. Festa A., D'Agostino Jr. R., Hanley A.J., Karter A.J., Saad M.F., and Haffner S.M. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53 (2004) 1549-1555
19. Blake D.R., Meigs J.B., Muller D.C., Najjar S.S., Andres R., and Nathan D.M. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 53 (2004) 2095-2100
20. Weyer C., Bogardus C., and Pratley R.E. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48 (1999) 2197-2203
21. Hanefeld M., Koehler C., Fuecker K., Henkel E., Schaper F., and Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. Diabetes Care 26 (2003) 868-874
22. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., and DeFronzo R.A. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90 (2005) 453-500
23. Carnevale G., Schianca P., Rossi A., Sainaghi P.P., Maduli E., and Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 26 (2003) 1333-1337
24. Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol 137 (1993) 959-965
25. Ferrara C.M., and Goldberg A.P. Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care 24 (2001) 245-249
26. Tripathy D., Almgren P., Tuomi T., and Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 27 (2004) 2204-2210
27. Bressler P., Bailey S.R., Matsuda M., and DeFronzo R.A. Insulin resistance and coronary artery disease. Diabetologia 39 (1996) 1345-1350
28. Muntner P., He J., Chen J., Fonseca V., and Whelton P.K. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 686-695
29. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J.C., Jakobs C., Bouter L.M., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18 (1998) 133-138
30. Becker A., Kostense P.J., Bos G., Heine R.J., Dekker J.M., Nijpels G., et al. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Int Med 253 (2003) 293-300
31. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
32. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
33. Fliser D., Kielstein J.T., Haller H., and Bode-Böger S.M. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease?. Kidney Int Suppl 84 (2003) S37-S40
34. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F.A., Tripepi G., Malatino L.S., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
35. Valkonen V.-P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakos J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
36. 12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 151 (2004) 483-489
37. Jonasson T.F., Hedner T., Hultberg B., and Ohlin H. Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease. Eur J Clin Invest 33 (2003) 543-549
38. Ziegler S., Mittermayer F., Plank C., Minar E., Wolzt M., and Schernthaner G.-H. Homocysteine-lowering therapy does not affect plasma ADMA concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 90 (2005) 2175-2178
39. Sydow K., Hornig B., Arakawa N., Bode-Böger S.M., Tsikas D., Munzel T., et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 9 (2004) 93-101
40. Stuhlinger M.C., Oka R.K., Graf E.E., Schmolzer I., Upson B.M., Kapoor O., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108 (2003) 933-938
41. Wanby P., Brattstrom L., Brudin L., Hultberg B., and Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 63 (2003) 347-353
42. Doshi S., McDowell I., Goodfellow J., Stabler S., Boger R., Allen R., et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 54 (2005) 351-360
43. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., and Stehouwer C.D. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 139 (1998) 197-198
44. Meigs J.B., Jacques P.F., Selhub J., Singer D.E., Nathan D.M., Rifai N., et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 24 (2001) 1403-1410
45. Martos R., Valle M., Morales R., Canete R., Gavilan M.I., and Sanchez-Margalet V. Hyperhomocysteinemia correlates with insulin resistance and low-grade systemic inflammation in obese prepubertal children. Metabolism 55 (2006) 72-77
46. Fonseca V.A., Fink L.M., and Kern P.A. Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis 167 (2003) 105-109
47. Rosolova H., Simon J., Mayer Jr. O., Racek J., Dierze T., and Jacobsen D.W. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 51 (2002) 93-98
48. Godsland I.F., Rosankiewicz J.R., Proudler A.J., and Johnston D.G. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 86 (2001) 719-723
49. Abbasi F., Facchini F., Humphreys M.H., and Reaven G.M. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atherosclerosis 146 (1999) 175-178
50. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., Di Minno G., Margaglione M., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53 (2004) 852-857
51. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva
52. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 (1979) E214-E223
53. Martens-Lobenhoffer J., Krug O., and Bode-Böger S.M. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 39 (2004) 1287-1294
54. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 Suppl 4 (1975) 5-40
55. Shinozaki K., Suzuki M., Ikebuchi M., Hara Y., and Harano Y. Demonstration of insulin resistance in coronary artery disease documented with coronary angiography. Diabetes Care 19 (1996) 1-7
56. Rewers M., Zaccaro D., D'Agostino R., Haffner S., Saad M.F., Selby J.V., et al. Insulin sensitivity, insulinemia, and coronary artery disease: Insulin Resistance Atherosclerosis Study. Diabetes Care 27 (2004) 781-787
57. Emoto M., Kanda H., Shoji T., Kawagishi T., Komatsu M., Mori K., et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24 (2001) 533-538
58. Araki A., Hosoi T., Orimo H., and Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism 54 (2005) 809-814
59. Buysschaert M., Dramasi A.-S., Wallemacq P.E., and Hermans M.P. Hyperhomocysteinemia in type 2 diabetes. Diabetes Care 23 (2000) 1816-1822
60. Okumura K., and Aso Y. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism 52 (2003) 1517-1522
61. Bostom A., Brosnan J.T., Hall B., Nadeau M.R., and Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116 (1995) 59-62
62. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
63. Fonseca V., Dicker-Brown A., Ranganathan S., Song W., Barnard R.J., Fink L., et al. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 49 (2000) 736-741
64. Fonseca V., Keebler M., Dicker-Brown A., DeSouza C., Poirier L.A., Murthy S.N., et al. The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism 51 (2002) 783-786
65. Poirier L.A., Brown A.T., Fink L.M., Wise C.K., Randolph C.J., Delongchamp R.R., et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 50 (2001) 1014-1018
66. Dicker-Brown A., Fonseca V.A., Fink L.M., and Kern P.A. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-β-synthase: studies in hepatocytes. Atherosclerosis 158 (2001) 297-301
67. Fonseca V.A., Mudaliar S., Schmidt B., Fink L.M., Kern P.A., and Henry R.R. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 47 (1998) 686-689
68. Arfvidsson B., Zachrisson H., Moller-Loswick A.C.V., Hyltander A., Sandstrom R., and Lundholm K. Effect of systemic hyperinsulinemia on amino acid flux across human legs in postaborptive state. Am J Physiol 260 (1991) E46-E52
69. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Mouslech T.F., Hitoglou-Makedou A.D., Stafylas P.C., et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 54 (2005) 1236-1242
70. Najib S., and Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol Endocrinol 27 (2001) 85-91
71. van Aken B.E., Jansen J., van Deventer S.J., and Reitsma P.H. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul Fibrinolysis 11 (2000) 159-164
72. Dalal S., Parkin S.M., Homer-Vanniasinkam S., and Nicolaou A. Effect of homocysteine on cytokine production by human endothelial cells and monocytes. Ann Clin Biochem 40 Pt 5 (2003) 534-541
73. Cardellini M., Perego L., D'Adamo M., Marini M.A., Procopio C., Hribal M.L., et al. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 28 (2005) 2007-2012
74. 6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103 (2001) 2788-2791
75. McCarty M.F. Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypotheses 55 (2000) 289-293
76. Reaven G.M. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 4 Suppl. 1 (2002) S13-S18
77. Weiss N., Heydrick S.J., Postea O., Keller C., Keaney Jr. J.F., and Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state-impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 41 (2003) 1455-1461
78. Zhang X., Li H., Jin H., Ebin Z., Brodsky S., and Goligorsky M.S. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol 279 (2000) F671-F678
79. Cosentino F., Hishikawa K., Katusic Z.S., and Luscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96 (1997) 25-28
80. Hofmann M.A., Kohl B., Zumbach M.S., Borcea V., Bierhaus A., Henkels M., et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21 (1998) 841-848
81. Shukla N., Thompson C.S., Angelini G.D., Mikhailidis D.P., and Jeremy J.Y. Homocysteine enhances impairment of endothelium-dependent relaxation and guanosine cyclic monophosphate formation in aortae from diabetic rabbits. Diabetologia 45 (2002) 1325-1331
82. Okada E., Oida K., Tada H., Asazuma K., Eguchi K., Tohda G., et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 22 (1999) 484-490
83. Gardemann A., Weidemann H., Philipp M., Katz N., Tillmanns H., Hehrlein F.W., et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 20 (1999) 584-592
84. ω-hydroxy-l-arginine as an intermediate. J Biol Chem 268 (1993) 14781-14787
85. Böger R.H., Bode-Böger S.M., Tsao P.S., Lin P.S., Chan J.R., and Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36 (2000) 2287-2295
86. Mittermayer F., Namiranian K., Pleiner J., Schaller G., and Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci 106 (2004) 577-581
87. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
88. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
89. Bachetti T., Comini L., Francolini G., Bastianon D., Valetti B., Cadei M., et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 37 (2004) 515-523
90. Dierkes J., Westphal S., Lobenhoffer-Martens J., Luley C., and Bode-Böger S.M. Fenofibrate increases the l-arginine:ADMA ratio by increase of l-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 173 (2004) 239-244
91. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., and Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
92. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
93. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
94. Marescau B., Nagels G., Possemiers I., De Broe M.E., Becaus I., Billiouw J.M., et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46 (1997) 1024-1031
95. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 354 (2006) 1629-1632
96. Böger R.H., Bode-Böger S.M., Sydow K., Heistad D.D., and Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 (2000) 1557-1564